← Leaderboards
Weiping Qin
James J Peters Va Medical Center
$0
Attributed
$0
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $0 · FY2015–25$1$1$1$0$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
VA$0 · 4
By mechanism
I01$0 · 4
Top collaborators
No co-investigators on record.
Most similar at James J Peters Va Medical Center
Same institution · by research overlap
- Christopher P Cardozo$1,203,045
- Christopher Cirnigliaro$0
Others in their field
Top investigators on “Future”
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$274,284,003
- Chanza Baytop · Westat, Inc.$271,217,917
- Everette D Joseph · Howard University$246,289,043
Research focus
FutureBone LossSpinal Cord InjuryBone ResorptionVeteransOsteogenesisRattusPreventOsteoclastogenesisBone MassOsteoblastsBoneMorbidity - Disease RateFractureBone MetabolismGene ExpressionMechanicsAntibodiesDeteriorationMolecularBloodAnimal ModelClinical TrialsInsight
Grant awards (17)
The Blockade of Siglec-15 as a Novel Approach to Improve Skeletal Integrity and Fracture Healing in Chronic SCI$0
I01 · FY2025 · VA · contact PI
The Blockade of Siglec-15 as a Novel Approach to Improve Skeletal Integrity and Fracture Healing in Chronic SCI$0
I01 · FY2024 · VA · contact PI
Novel Pharmacological and Non-pharmacological Interventions for Bone Loss in SCI$0
I01 · FY2023 · VA · contact PI
Novel Pharmacological and Non-pharmacological Interventions for Bone Loss in SCI$0
I01 · FY2022 · VA · contact PI
Novel Pharmacological and Non-pharmacological Interventions for Bone Loss in SCI$0
I01 · FY2021 · VA · contact PI
Novel Pharmacological and Non-pharmacological Interventions for Bone Loss in SCI$0
I01 · FY2020 · VA · contact PI
Novel Pharmacological and Non-pharmacological Interventions for Bone Loss in SCI$0
I01 · FY2019 · VA · contact PI
Novel Pharmacological and Non-pharmacological Interventions for Bone Loss in SCI$0
I01 · FY2018 · VA · contact PI
ES and Androgens in Bone Loss after SCI: Synergistic Effects and Mechanisms$0
I01 · FY2017 · VA · contact PI
Sclerostin Antagonism and the Osteocytes Role Prevention of Bone Loss after SCI$0
I01 · FY2017 · VA · contact PI
Novel Pharmacological and Non-pharmacological Interventions for Bone Loss in SCI$0
I01 · FY2017 · VA · contact PI
Sclerostin Antagonism and the Osteocytes Role Prevention of Bone Loss after SCI$0
I01 · FY2016 · VA · contact PI
Sclerostin Antagonism and the Osteocytes Role Prevention of Bone Loss after SCI$0
I01 · FY2016 · VA · contact PI
ES and Androgens in Bone Loss after SCI: Synergistic Effects and Mechanisms$0
I01 · FY2015 · VA · contact PI
ES and Androgens in Bone Loss after SCI: Synergistic Effects and Mechanisms$0
I01 · FY2015 · VA · contact PI
ES and Androgens in Bone Loss after SCI: Synergistic Effects and Mechanisms$0
I01 · FY2015 · VA · contact PI
Sclerostin Antagonism and the Osteocytes Role Prevention of Bone Loss after SCI$0
I01 · FY2015 · VA · contact PI